Sort   by:  
 Page size 
GenomicsRNA seq analysis of SHP099 treated Leukemic Cells Expressing Genetic and Epigenetic Mutations
RNA seq analysis of SHP099 treated Leukemic Cells Expressing Genetic and Epigenetic Mutations
PRJNA556634 | ENA
UnknownIntraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect.
Not available
S-EPMC8857578 | biostudies-literature
UnknownSHP2 inhibition by SHP099 attenuates IL-6-driven osteoclastogenesis in growth plate injury.
Not available
S-EPMC12394037 | biostudies-literature
UnknownControlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Not available
S-EPMC9054207 | biostudies-literature
UnknownCombined administration of SHP2 inhibitor SHP099 and the α7nAChR agonist PNU282987 protect mice against DSS‑induced colitis.
Not available
S-EPMC7411392 | biostudies-literature
TranscriptomicsRNA seq analysis of SHP099 treated Leukemic Cells Expressing Genetic and Epigenetic Mutations
10 to 30% normal karyotype acute myeloid leukemia (AML) patients express mutations in regulators of DNA methylation such as TET2 or DNMT3A in conjunction with activating mutation in receptor tyrosine kinase, FLT3, which can be present in up to 50% of normal karyotype AML patients. These patients hav...
ORGANISM(S): Mus musculus 
2019-07-26 | GSE134843 | GEO
UnknownSHP099-containing multi-targeting hydrogel promotes rapid skin reconstruction through modulating a variety of cells.
Not available
S-EPMC12009829 | biostudies-literature
GenomicsSingle-cell transcriptomics analysis of the tumor microenvironment from murine MC38 xenografts upon SHP099 treatment
Single-cell transcriptomics analysis of the tumor microenvironment from murine MC38 xenografts upon SHP099 treatment
PRJNA692434 | ENA
ProteomicsDual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progressi...
ORGANISM(S): Homo sapiens (Human) 
2024-11-20 | PXD036000 | Pride
Shp099 Therapeutics Patient-derived xenograft Kinase inhibitor Genetically engineered mouse model Hydroxychloroquine Neurofibromatosis type 1 Trametinib Kinome 
TranscriptomicsTargeting PDGFRa-activated Glioblastoma through Specific Inhibition of SHP-2-mediated Signaling
SHP-2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is critical for PDGFR-driven gliomagenesis. SHP099, a novel and potent SHP-2 inhibitor, preferentially attenuated the tumorigenicity of GBM and glioma stem-like cells (GSCs) compared to normal brain cells or neural p...
ORGANISM(S): Mus musculus 
2021-02-20 | GSE126892 | GEO
Sort   by:  
 Page size